0 TSX News - November 26, 2018IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018DARTMOUTH, Nova Scotia, Nov. 26, 2018 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, […]Read More
0 TSX News - November 26, 2018Knight Therapeutics Announces Canadian Regulatory Approval for ILUVIEN®MONTREAL, Nov. 26, 2018 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today […]Read More
0 TSX News - November 26, 2018Cogeco Inc. Announces the Completion of Its Acquisition of 10 Radio Stations From RNC Média Inc.MONTREAL, Nov. 26, 2018 (GLOBE NEWSWIRE) — Cogeco Inc. (“Cogeco” or the “Company”) is pleased to announce the completion of […]Read More
0 TSX News - November 26, 2018Tellza UpdateTORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) — Tellza Inc. (“Tellza” or the “Company”) (TSX:TEL) announced today that it received a […]Read More
0 TSX News - November 26, 2018Strad Announces Renewal of Normal Course Issuer BidCALGARY, Alberta , Nov. 26, 2018 (GLOBE NEWSWIRE) — Strad Energy Services Ltd. (“Strad” or the “Company”) (TSX:SDY) today announced […]Read More
0 TSX News - November 26, 2018Gibson Energy Announces Exit from Non-Core Environmental Services North and Wholesale Propane Businesses for Proceeds of Approximately $100 MillionAll financial figures are in Canadian dollars unless otherwise noted CALGARY, Alberta, Nov. 26, 2018 (GLOBE NEWSWIRE) — Gibson Energy […]Read More
0 TSX News - November 26, 2018Spectral Announces Publication of the post hoc analysis of EUPHRATES trial in Intensive Care MedicineTORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing […]Read More
0 TSX News - November 26, 2018CN’s Ruest Named Railroader of the YearMONTREAL, Nov. 26, 2018 (GLOBE NEWSWIRE) — Today, Railway Age announced that the 56th annual recipient of the Railroader of […]Read More
0 TSX News - November 26, 2018Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological MalignanciesSAN DIEGO and TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company […]Read More
0 TSX News - November 26, 2018Auryn Identifies Multiple Copper-Gold Drill Targets at SombreroVANCOUVER, British Columbia, Nov. 26, 2018 (GLOBE NEWSWIRE) — Auryn Resources Inc. (TSX: AUG, NYSE AMERICAN: AUG, “Auryn” or the […]Read More